WILMINGTON, MA--(Marketwire - Sep 24, 2012) - Implant Sciences Corporation (OTCQB: [ IMSC ]), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has appointed Ms. Nav Mosey as the U.S. Air Cargo Sales Manager. This newly created role will position the Company to expand on its recent successes with both the handheld and desktop trace detection products in the global air cargo market. The Company's Quantum Sniffer™ QS-B220 desktop explosives and narcotics trace detectors is currently being evaluated for air cargo screening by the U.S. Transportation and Security Administration (TSA).

Ms. Mosey was Sales Manager for Rapiscan Systems, a leading global supplier of security inspection solutions. At Rapiscan, Ms. Mosey generated millions of dollars in sales, opened new markets, developed sales channels, and introduced new products to U.S. and foreign governments, military and security forces, and commercial customers. Prior to Rapiscan, she held sales positions at high tech firms including Coradiant, Avcom Technologies, and Ingram Micro Canada. She received her Bachelor's degree in Business Administration from British Columbia Institute of Technology.

"Air cargo screening is a large market that we intend to aggressively pursue in the U.S. as well as abroad. Nav's industry experience, strength in cultivating customer relationships, and enthusiasm towards our products all combine to make her a sales manager who, we believe, can optimally ramp up Implant Sciences' market share in air cargo screening," stated Dr. Darryl Jones, Implant Sciences' Vice President of Sales and Marketing.

"We continue to attract top industry talent from across the security equipment industry. Executives, advisors, operations and sales managers from top-tier competitors have chosen to join Implant Sciences based upon the strength of our next generation technologies and products. We are very confident in our team's capacity to execute on the tremendous market opportunity that our products are well-positioned to serve," added Implant Sciences' President and CEO, Glenn D. Bolduc.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at [ www.implantsciences.com ].

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.